Effect of Aprepitant on the Pharmacokinetics of Intravenous Midazolam
| Autor: | James Dru, Diana V. Selverian, M.L Constanzer, Tuli Ahmed, Kevin J. Petty, Anup K. Majumdar, Howard E. Greenberg, Jacqueline B. McCrea, Kerri X. Yan, Glen S. Frick, Suna Barlas, Walter K. Kraft |
|---|---|
| Rok vydání: | 2007 |
| Předmět: |
Adult
Male genetic structures Metabolic Clearance Rate medicine.drug_class Midazolam Morpholines Cytochrome P-450 Enzyme System Pharmacokinetics mental disorders Cytochrome P-450 CYP3A Humans Medicine Antiemetic heterocyclic compounds Pharmacology (medical) Aprepitant Pharmacology Cross-Over Studies business.industry Perioperative Crossover study Confidence interval surgical procedures operative Area Under Curve Anesthesia Injections Intravenous Antiemetics Female business psychological phenomena and processes Half-Life medicine.drug |
| Zdroj: | The Journal of Clinical Pharmacology. 47:744-750 |
| ISSN: | 0091-2700 |
| Popis: | Oral aprepitant 125 mg, an antiemetic and a moderate inhibitor of the metabolism of oral midazolam, was assessed for interaction with intravenous midazolam in 12 subjects randomized to intravenous midazolam 2 mg +/- oral aprepitant 125 mg. The hypothesis was that midazolam AUC would not change by more than 2-fold (consistent with no more than weak inhibition) when midazolam + aprepitant was compared with midazolam alone. An AUC geometric mean ratio (midazolam + aprepitant/midazolam) with 90% confidence interval upper bound < or =2.0 (an increase in midazolam felt to be of modest clinical significance in the highly monitored perioperative period) was prespecified. Aprepitant increased intravenous midazolam AUC(0-infinity) 1.47-fold (90% confidence interval, 1.36-1.59), which fell within the prespecified criterion. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text